Status:
COMPLETED
Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)
Lead Sponsor:
PETHEMA Foundation
Conditions:
Relapsed and Refractory Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Multiple myeloma (MM) is a plasma cell neoplasm representing the second most common type of hematologic tumor after lymphomas. The incorporation of novel agents such as bortezomib, lenalidomide, or th...
Detailed Description
This is a national, multicentre, observational, retrospective, open-label, non-randomized, non-interventional study to evaluate the degree of compliance at PETHEMA centres in Spain with the clinical p...
Eligibility Criteria
Inclusion
- Patients treated with POMCIDEX during the period 01/01/2015 and 01/04/2018 in accordance with the PETHEMA clinical practice guidelines. The inclusion criteria in the guidelines are those specified in the clinical practice guidelines
Exclusion
- Patients who have not been treated according to the clinical practice guidelines during the specified period
Key Trial Info
Start Date :
April 27 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 14 2020
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT03477643
Start Date
April 27 2018
End Date
July 14 2020
Last Update
February 5 2021
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Sant Joan de Déu
Barcelona, Spain
2
Hospital Donostia-Donostia Ospitalea
Donostia / San Sebastian, Spain
3
Hospital Universitario Virgen de Las Nieves
Granada, Spain
4
Hospital General San Jorge - Huesca
Huesca, Spain